PARPi has a potential for use in HCC treatment through at least two mechanisms: first, by the catalytic inhibition of PARP activity after its binding to DNA damage and second, as a consequence of this inactivation of PARP activity, by the trapping of the PARP protein on DNA damage that would block replication. Here, PARP1 is linked to hepatocellular carcinoma.